cgrp receptor antagonist rat cgrp8 37 Search Results


cgrp peptide antagonist cgrp8 37  (Tocris)
93
Tocris cgrp peptide antagonist cgrp8 37
Cgrp Peptide Antagonist Cgrp8 37, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cgrp+receptor+antagonist+rat+cgrp8+37/CGRP+8-37+(rat)/pm26574822-151-10-16
Average 93 stars, based on 1 article reviews
cgrp peptide antagonist cgrp8 37 - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
cgrp 8 37  (Tocris)
93
Tocris cgrp 8 37
Cgrp 8 37, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cgrp+receptor+antagonist+rat+cgrp8+37/CGRP+8-37+(rat)/pmc03116081__NIHMS280293___supplement___01-51-5-7
Average 93 stars, based on 1 article reviews
cgrp 8 37 - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
rat cgrp 8–37  (Neo MPS Inc)
90
Neo MPS Inc rat cgrp 8–37
Rat Cgrp 8–37, supplied by Neo MPS Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cgrp+receptor+antagonist+rat+cgrp8+37/rat+%CE%B1+cgrp/pmc03010590-222-3-9
Average 90 stars, based on 1 article reviews
rat cgrp 8–37 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
1-cgrp8-37  (Bachem)
90
Bachem 1-cgrp8-37
1 Cgrp8 37, supplied by Bachem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cgrp+receptor+antagonist+rat+cgrp8+37/cgrp8+37/10__1523_slash_JNEUROSCI__1137___21__2022_ascii32_-69-0-8
Average 90 stars, based on 1 article reviews
1-cgrp8-37 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
rat cgrp 1 receptor antagonist  (Tocris)
91
Tocris rat cgrp 1 receptor antagonist
Rat Cgrp 1 Receptor Antagonist, supplied by Tocris, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cgrp+receptor+antagonist+rat+cgrp8+37/CGRP+(rat)/pmc03543477-43-4-11
Average 91 stars, based on 1 article reviews
rat cgrp 1 receptor antagonist - by Bioz Stars, 2026-10
91/100 stars
  Buy from Supplier
cgrp receptor antagonist rat cgrp8 37  (MedChemExpress)
94
MedChemExpress cgrp receptor antagonist rat cgrp8 37
CGRP protects BMSCs from serum deprivation-induced apoptosis: (A) representative flow cytometric dot plots showing Annexin V-FITC/PI double staining after 24 and 48 h of serum-free culture. Four distinct cell populations are displayed: viable cells (Annexin V − /PI − , lower left quadrant), early apoptotic cells (Annexin V + /PI − , lower right quadrant), late apoptotic cells (Annexin V + /PI + , upper right quadrant), and necrotic cells (Annexin V − /PI + , upper left quadrant). Representative plots show control, CGRP (10 −8 M), CGRP <t>+</t> <t>CGRP8-37</t> (10 −8 M CGRP + 10 −6 M CGRP8-37), and CGRP + H89 (10 −8 M CGRP + 0.2 μg/mL H89) treatment groups. (B) Quantitative analysis of the total apoptotic rate calculated as the sum of early apoptotic (Annexin V + /PI − ) and late apoptotic (Annexin V + /PI + ) cell percentages. CGRP treatment significantly reduced total apoptosis compared to control. CGRP8-37 and H89 co-treatments abolished CGRP’s protective effects, with apoptosis rates returning to control levels. Data represent mean ± SD from independent experiments (n = 6). *P < 0.05 compared to the control group; *P < 0.05 compared to the CGRP group using one-way ANOVA followed by Tukey’s post hoc test.
Cgrp Receptor Antagonist Rat Cgrp8 37, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cgrp+receptor+antagonist+rat+cgrp8+37/Rat+CGRP/pmc12504274-42-7-21
Average 94 stars, based on 1 article reviews
cgrp receptor antagonist rat cgrp8 37 - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
rat -cgrp(8-37)  (Bachem)
90
Bachem rat -cgrp(8-37)
CGRP protects BMSCs from serum deprivation-induced apoptosis: (A) representative flow cytometric dot plots showing Annexin V-FITC/PI double staining after 24 and 48 h of serum-free culture. Four distinct cell populations are displayed: viable cells (Annexin V − /PI − , lower left quadrant), early apoptotic cells (Annexin V + /PI − , lower right quadrant), late apoptotic cells (Annexin V + /PI + , upper right quadrant), and necrotic cells (Annexin V − /PI + , upper left quadrant). Representative plots show control, CGRP (10 −8 M), CGRP <t>+</t> <t>CGRP8-37</t> (10 −8 M CGRP + 10 −6 M CGRP8-37), and CGRP + H89 (10 −8 M CGRP + 0.2 μg/mL H89) treatment groups. (B) Quantitative analysis of the total apoptotic rate calculated as the sum of early apoptotic (Annexin V + /PI − ) and late apoptotic (Annexin V + /PI + ) cell percentages. CGRP treatment significantly reduced total apoptosis compared to control. CGRP8-37 and H89 co-treatments abolished CGRP’s protective effects, with apoptosis rates returning to control levels. Data represent mean ± SD from independent experiments (n = 6). *P < 0.05 compared to the control group; *P < 0.05 compared to the CGRP group using one-way ANOVA followed by Tukey’s post hoc test.
Rat Cgrp(8 37), supplied by Bachem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cgrp+receptor+antagonist+rat+cgrp8+37/rat+cgrp/pm17660394-57-2-8
Average 90 stars, based on 1 article reviews
rat -cgrp(8-37) - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
cgrp8-37  (Microm International GmbH)
90
Microm International GmbH cgrp8-37
CGRP protects BMSCs from serum deprivation-induced apoptosis: (A) representative flow cytometric dot plots showing Annexin V-FITC/PI double staining after 24 and 48 h of serum-free culture. Four distinct cell populations are displayed: viable cells (Annexin V − /PI − , lower left quadrant), early apoptotic cells (Annexin V + /PI − , lower right quadrant), late apoptotic cells (Annexin V + /PI + , upper right quadrant), and necrotic cells (Annexin V − /PI + , upper left quadrant). Representative plots show control, CGRP (10 −8 M), CGRP <t>+</t> <t>CGRP8-37</t> (10 −8 M CGRP + 10 −6 M CGRP8-37), and CGRP + H89 (10 −8 M CGRP + 0.2 μg/mL H89) treatment groups. (B) Quantitative analysis of the total apoptotic rate calculated as the sum of early apoptotic (Annexin V + /PI − ) and late apoptotic (Annexin V + /PI + ) cell percentages. CGRP treatment significantly reduced total apoptosis compared to control. CGRP8-37 and H89 co-treatments abolished CGRP’s protective effects, with apoptosis rates returning to control levels. Data represent mean ± SD from independent experiments (n = 6). *P < 0.05 compared to the control group; *P < 0.05 compared to the CGRP group using one-way ANOVA followed by Tukey’s post hoc test.
Cgrp8 37, supplied by Microm International GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cgrp+receptor+antagonist+rat+cgrp8+37/cgrp+peptide/pmc01909800-9-9-9
Average 90 stars, based on 1 article reviews
cgrp8-37 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
hcgrp 8−37  (Bachem)
90
Bachem hcgrp 8−37
CGRP protects BMSCs from serum deprivation-induced apoptosis: (A) representative flow cytometric dot plots showing Annexin V-FITC/PI double staining after 24 and 48 h of serum-free culture. Four distinct cell populations are displayed: viable cells (Annexin V − /PI − , lower left quadrant), early apoptotic cells (Annexin V + /PI − , lower right quadrant), late apoptotic cells (Annexin V + /PI + , upper right quadrant), and necrotic cells (Annexin V − /PI + , upper left quadrant). Representative plots show control, CGRP (10 −8 M), CGRP <t>+</t> <t>CGRP8-37</t> (10 −8 M CGRP + 10 −6 M CGRP8-37), and CGRP + H89 (10 −8 M CGRP + 0.2 μg/mL H89) treatment groups. (B) Quantitative analysis of the total apoptotic rate calculated as the sum of early apoptotic (Annexin V + /PI − ) and late apoptotic (Annexin V + /PI + ) cell percentages. CGRP treatment significantly reduced total apoptosis compared to control. CGRP8-37 and H89 co-treatments abolished CGRP’s protective effects, with apoptosis rates returning to control levels. Data represent mean ± SD from independent experiments (n = 6). *P < 0.05 compared to the control group; *P < 0.05 compared to the CGRP group using one-way ANOVA followed by Tukey’s post hoc test.
Hcgrp 8−37, supplied by Bachem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cgrp+receptor+antagonist+rat+cgrp8+37/hcgrp+8+37/pmc02327047-138-9-14
Average 90 stars, based on 1 article reviews
hcgrp 8−37 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
substance p, rat α -cgrp and rat α -cgrp 8–37  (Auspep Pty)
90
Auspep Pty substance p, rat α -cgrp and rat α -cgrp 8–37
CGRP protects BMSCs from serum deprivation-induced apoptosis: (A) representative flow cytometric dot plots showing Annexin V-FITC/PI double staining after 24 and 48 h of serum-free culture. Four distinct cell populations are displayed: viable cells (Annexin V − /PI − , lower left quadrant), early apoptotic cells (Annexin V + /PI − , lower right quadrant), late apoptotic cells (Annexin V + /PI + , upper right quadrant), and necrotic cells (Annexin V − /PI + , upper left quadrant). Representative plots show control, CGRP (10 −8 M), CGRP <t>+</t> <t>CGRP8-37</t> (10 −8 M CGRP + 10 −6 M CGRP8-37), and CGRP + H89 (10 −8 M CGRP + 0.2 μg/mL H89) treatment groups. (B) Quantitative analysis of the total apoptotic rate calculated as the sum of early apoptotic (Annexin V + /PI − ) and late apoptotic (Annexin V + /PI + ) cell percentages. CGRP treatment significantly reduced total apoptosis compared to control. CGRP8-37 and H89 co-treatments abolished CGRP’s protective effects, with apoptosis rates returning to control levels. Data represent mean ± SD from independent experiments (n = 6). *P < 0.05 compared to the control group; *P < 0.05 compared to the CGRP group using one-way ANOVA followed by Tukey’s post hoc test.
Substance P, Rat α Cgrp And Rat α Cgrp 8–37, supplied by Auspep Pty, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cgrp+receptor+antagonist+rat+cgrp8+37/human+cgrp/pmc01574021-111-0-13
Average 90 stars, based on 1 article reviews
substance p, rat α -cgrp and rat α -cgrp 8–37 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
rat calcitonin gene-related peptide ( cgrp)  (Bachem)
90
Bachem rat calcitonin gene-related peptide ( cgrp)
CGRP protects BMSCs from serum deprivation-induced apoptosis: (A) representative flow cytometric dot plots showing Annexin V-FITC/PI double staining after 24 and 48 h of serum-free culture. Four distinct cell populations are displayed: viable cells (Annexin V − /PI − , lower left quadrant), early apoptotic cells (Annexin V + /PI − , lower right quadrant), late apoptotic cells (Annexin V + /PI + , upper right quadrant), and necrotic cells (Annexin V − /PI + , upper left quadrant). Representative plots show control, CGRP (10 −8 M), CGRP <t>+</t> <t>CGRP8-37</t> (10 −8 M CGRP + 10 −6 M CGRP8-37), and CGRP + H89 (10 −8 M CGRP + 0.2 μg/mL H89) treatment groups. (B) Quantitative analysis of the total apoptotic rate calculated as the sum of early apoptotic (Annexin V + /PI − ) and late apoptotic (Annexin V + /PI + ) cell percentages. CGRP treatment significantly reduced total apoptosis compared to control. CGRP8-37 and H89 co-treatments abolished CGRP’s protective effects, with apoptosis rates returning to control levels. Data represent mean ± SD from independent experiments (n = 6). *P < 0.05 compared to the control group; *P < 0.05 compared to the CGRP group using one-way ANOVA followed by Tukey’s post hoc test.
Rat Calcitonin Gene Related Peptide ( Cgrp), supplied by Bachem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cgrp+receptor+antagonist+rat+cgrp8+37/calcitonin+gene+related+peptide/pmc02829526-91-0-15
Average 90 stars, based on 1 article reviews
rat calcitonin gene-related peptide ( cgrp) - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
synthetic rat am  (Peptide Institute)
86
Peptide Institute synthetic rat am
CGRP protects BMSCs from serum deprivation-induced apoptosis: (A) representative flow cytometric dot plots showing Annexin V-FITC/PI double staining after 24 and 48 h of serum-free culture. Four distinct cell populations are displayed: viable cells (Annexin V − /PI − , lower left quadrant), early apoptotic cells (Annexin V + /PI − , lower right quadrant), late apoptotic cells (Annexin V + /PI + , upper right quadrant), and necrotic cells (Annexin V − /PI + , upper left quadrant). Representative plots show control, CGRP (10 −8 M), CGRP <t>+</t> <t>CGRP8-37</t> (10 −8 M CGRP + 10 −6 M CGRP8-37), and CGRP + H89 (10 −8 M CGRP + 0.2 μg/mL H89) treatment groups. (B) Quantitative analysis of the total apoptotic rate calculated as the sum of early apoptotic (Annexin V + /PI − ) and late apoptotic (Annexin V + /PI + ) cell percentages. CGRP treatment significantly reduced total apoptosis compared to control. CGRP8-37 and H89 co-treatments abolished CGRP’s protective effects, with apoptosis rates returning to control levels. Data represent mean ± SD from independent experiments (n = 6). *P < 0.05 compared to the control group; *P < 0.05 compared to the CGRP group using one-way ANOVA followed by Tukey’s post hoc test.
Synthetic Rat Am, supplied by Peptide Institute, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cgrp+receptor+antagonist+rat+cgrp8+37/am+rat+synthetic/10__1210_slash_en__139__8__3432-62-0-13
Average 86 stars, based on 1 article reviews
synthetic rat am - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

Image Search Results


CGRP protects BMSCs from serum deprivation-induced apoptosis: (A) representative flow cytometric dot plots showing Annexin V-FITC/PI double staining after 24 and 48 h of serum-free culture. Four distinct cell populations are displayed: viable cells (Annexin V − /PI − , lower left quadrant), early apoptotic cells (Annexin V + /PI − , lower right quadrant), late apoptotic cells (Annexin V + /PI + , upper right quadrant), and necrotic cells (Annexin V − /PI + , upper left quadrant). Representative plots show control, CGRP (10 −8 M), CGRP + CGRP8-37 (10 −8 M CGRP + 10 −6 M CGRP8-37), and CGRP + H89 (10 −8 M CGRP + 0.2 μg/mL H89) treatment groups. (B) Quantitative analysis of the total apoptotic rate calculated as the sum of early apoptotic (Annexin V + /PI − ) and late apoptotic (Annexin V + /PI + ) cell percentages. CGRP treatment significantly reduced total apoptosis compared to control. CGRP8-37 and H89 co-treatments abolished CGRP’s protective effects, with apoptosis rates returning to control levels. Data represent mean ± SD from independent experiments (n = 6). *P < 0.05 compared to the control group; *P < 0.05 compared to the CGRP group using one-way ANOVA followed by Tukey’s post hoc test.

Journal: Frontiers in Bioengineering and Biotechnology

Article Title: CGRP-dependent molecular signaling drives bone marrow stem cell osteogenesis in distraction osteogenesis

doi: 10.3389/fbioe.2025.1641476

Figure Lengend Snippet: CGRP protects BMSCs from serum deprivation-induced apoptosis: (A) representative flow cytometric dot plots showing Annexin V-FITC/PI double staining after 24 and 48 h of serum-free culture. Four distinct cell populations are displayed: viable cells (Annexin V − /PI − , lower left quadrant), early apoptotic cells (Annexin V + /PI − , lower right quadrant), late apoptotic cells (Annexin V + /PI + , upper right quadrant), and necrotic cells (Annexin V − /PI + , upper left quadrant). Representative plots show control, CGRP (10 −8 M), CGRP + CGRP8-37 (10 −8 M CGRP + 10 −6 M CGRP8-37), and CGRP + H89 (10 −8 M CGRP + 0.2 μg/mL H89) treatment groups. (B) Quantitative analysis of the total apoptotic rate calculated as the sum of early apoptotic (Annexin V + /PI − ) and late apoptotic (Annexin V + /PI + ) cell percentages. CGRP treatment significantly reduced total apoptosis compared to control. CGRP8-37 and H89 co-treatments abolished CGRP’s protective effects, with apoptosis rates returning to control levels. Data represent mean ± SD from independent experiments (n = 6). *P < 0.05 compared to the control group; *P < 0.05 compared to the CGRP group using one-way ANOVA followed by Tukey’s post hoc test.

Article Snippet: Rat α-calcitonin gene-related peptide (rat α-CGRP, HY-P0203), CGRP receptor antagonist rat CGRP8-37 (HY-P0209), and PKA inhibitor H89 (HY-15979) were purchased from MCE (China).

Techniques: Double Staining, Control

CGRP enhances BMSC osteogenic differentiation: (A) Alizarin Red S staining showing calcium nodule formation at days 14 and 21 of osteogenic induction. CGRP treatment resulted in more numerous and deeper-stained orange-red calcified nodules compared to controls. CGRP8-37 and H89 treatments significantly reduced CGRP-induced mineralization enhancement (scale bars: 50 μm). (B) Quantitative analysis of Alizarin Red staining using the cetylpyridinium chloride (CPC) extraction method. CGRP treatment showed 3.7-fold and 3.5-fold increases in mineralization at 14 and 21 days, respectively, compared to controls. Both CGRP8-37 and H89 treatments effectively blocked CGRP-induced mineralization enhancement. (C) Alkaline phosphatase (ALP) staining demonstrating enhanced early osteogenic marker expression at days 4 and 7. Purple precipitates indicate ALP activity (scale bars: 50 μm). CGRP8-37 and H89 treatments inhibited CGRP-induced osteogenic enhancement. (D) Quantitative ALP activity measurements normalized to total protein content. CGRP treatment demonstrated 3.7-fold and 3.9-fold increases in ALP activity at 4 and 7 days, respectively, compared to controls. CGRP + CGRP8-37 and CGRP + H89 groups showed significantly reduced ALP activity compared to CGRP alone, confirming that both receptor blockade and PKA pathway inhibition prevent CGRP’s osteogenic enhancing effects.

Journal: Frontiers in Bioengineering and Biotechnology

Article Title: CGRP-dependent molecular signaling drives bone marrow stem cell osteogenesis in distraction osteogenesis

doi: 10.3389/fbioe.2025.1641476

Figure Lengend Snippet: CGRP enhances BMSC osteogenic differentiation: (A) Alizarin Red S staining showing calcium nodule formation at days 14 and 21 of osteogenic induction. CGRP treatment resulted in more numerous and deeper-stained orange-red calcified nodules compared to controls. CGRP8-37 and H89 treatments significantly reduced CGRP-induced mineralization enhancement (scale bars: 50 μm). (B) Quantitative analysis of Alizarin Red staining using the cetylpyridinium chloride (CPC) extraction method. CGRP treatment showed 3.7-fold and 3.5-fold increases in mineralization at 14 and 21 days, respectively, compared to controls. Both CGRP8-37 and H89 treatments effectively blocked CGRP-induced mineralization enhancement. (C) Alkaline phosphatase (ALP) staining demonstrating enhanced early osteogenic marker expression at days 4 and 7. Purple precipitates indicate ALP activity (scale bars: 50 μm). CGRP8-37 and H89 treatments inhibited CGRP-induced osteogenic enhancement. (D) Quantitative ALP activity measurements normalized to total protein content. CGRP treatment demonstrated 3.7-fold and 3.9-fold increases in ALP activity at 4 and 7 days, respectively, compared to controls. CGRP + CGRP8-37 and CGRP + H89 groups showed significantly reduced ALP activity compared to CGRP alone, confirming that both receptor blockade and PKA pathway inhibition prevent CGRP’s osteogenic enhancing effects.

Article Snippet: Rat α-calcitonin gene-related peptide (rat α-CGRP, HY-P0203), CGRP receptor antagonist rat CGRP8-37 (HY-P0209), and PKA inhibitor H89 (HY-15979) were purchased from MCE (China).

Techniques: Staining, Extraction, Marker, Expressing, Activity Assay, Inhibition

CGRP activates the cAMP/PKA signaling pathway in BMSCs: (A) ELISA quantification of intracellular cAMP levels 30 min post-treatment. CGRP rapidly increased cAMP concentration, blocked by CGRP8-37 and H89. Data represent mean ± SD (n = 6). (B-D) Western blot analysis of PKA and CREB phosphorylation at 30 min. Representative blots and quantitative analysis of p-PKA/PKA and p-CREB/CREB ratios. Data represent mean ± SD. *P < 0.05.

Journal: Frontiers in Bioengineering and Biotechnology

Article Title: CGRP-dependent molecular signaling drives bone marrow stem cell osteogenesis in distraction osteogenesis

doi: 10.3389/fbioe.2025.1641476

Figure Lengend Snippet: CGRP activates the cAMP/PKA signaling pathway in BMSCs: (A) ELISA quantification of intracellular cAMP levels 30 min post-treatment. CGRP rapidly increased cAMP concentration, blocked by CGRP8-37 and H89. Data represent mean ± SD (n = 6). (B-D) Western blot analysis of PKA and CREB phosphorylation at 30 min. Representative blots and quantitative analysis of p-PKA/PKA and p-CREB/CREB ratios. Data represent mean ± SD. *P < 0.05.

Article Snippet: Rat α-calcitonin gene-related peptide (rat α-CGRP, HY-P0203), CGRP receptor antagonist rat CGRP8-37 (HY-P0209), and PKA inhibitor H89 (HY-15979) were purchased from MCE (China).

Techniques: Enzyme-linked Immunosorbent Assay, Concentration Assay, Western Blot, Phospho-proteomics

CGRP enhances biomechanical properties of regenerated bone: three-point bending test results at 6 weeks of consolidation showing (A) ultimate load, (B) energy to failure, and (C) stiffness measurements. CGRP treatment significantly improved all mechanical parameters compared to controls. CGRP8-37 and H89 abolished these beneficial effects. Data represent mean ± SD. *P < 0.05.

Journal: Frontiers in Bioengineering and Biotechnology

Article Title: CGRP-dependent molecular signaling drives bone marrow stem cell osteogenesis in distraction osteogenesis

doi: 10.3389/fbioe.2025.1641476

Figure Lengend Snippet: CGRP enhances biomechanical properties of regenerated bone: three-point bending test results at 6 weeks of consolidation showing (A) ultimate load, (B) energy to failure, and (C) stiffness measurements. CGRP treatment significantly improved all mechanical parameters compared to controls. CGRP8-37 and H89 abolished these beneficial effects. Data represent mean ± SD. *P < 0.05.

Article Snippet: Rat α-calcitonin gene-related peptide (rat α-CGRP, HY-P0203), CGRP receptor antagonist rat CGRP8-37 (HY-P0209), and PKA inhibitor H89 (HY-15979) were purchased from MCE (China).

Techniques: